HF Advisory Group LLC Grows Stock Position in Kenvue Inc. (NYSE:KVUE)

HF Advisory Group LLC increased its holdings in Kenvue Inc. (NYSE:KVUE) by 15.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 110,205 shares of the company’s stock after acquiring an additional 14,686 shares during the period. Kenvue makes up about 1.2% of HF Advisory Group LLC’s holdings, making the stock its 21st largest holding. HF Advisory Group LLC’s holdings in Kenvue were worth $2,549,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Yacktman Asset Management LP lifted its stake in Kenvue by 2.9% during the third quarter. Yacktman Asset Management LP now owns 8,381,404 shares of the company’s stock worth $193,862,000 after purchasing an additional 232,631 shares in the last quarter. National Pension Service boosted its holdings in Kenvue by 14.5% during the 3rd quarter. National Pension Service now owns 2,829,772 shares of the company’s stock valued at $65,453,000 after acquiring an additional 357,672 shares during the period. Cohen Capital Management Inc. grew its position in Kenvue by 1.6% in the 3rd quarter. Cohen Capital Management Inc. now owns 168,193 shares of the company’s stock valued at $3,890,000 after acquiring an additional 2,640 shares in the last quarter. CORDA Investment Management LLC. increased its stake in Kenvue by 1.3% during the third quarter. CORDA Investment Management LLC. now owns 1,235,630 shares of the company’s stock worth $28,580,000 after purchasing an additional 16,270 shares during the period. Finally, Allen Wealth Management LLC increased its stake in Kenvue by 14.4% during the third quarter. Allen Wealth Management LLC now owns 76,558 shares of the company’s stock worth $1,771,000 after purchasing an additional 9,618 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 0.8 %

KVUE opened at $23.23 on Wednesday. The business’s 50-day simple moving average is $22.57 and its 200-day simple moving average is $20.47. The company has a market cap of $44.48 billion, a P/E ratio of 40.04, a PEG ratio of 2.97 and a beta of 1.36. Kenvue Inc. has a one year low of $17.67 and a one year high of $23.57. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter last year, the company earned $0.32 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts expect that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.53%. Kenvue’s dividend payout ratio is currently 141.38%.

Analyst Ratings Changes

A number of research analysts recently weighed in on KVUE shares. Citigroup dropped their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.